Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors

Annals of Pharmacotherapy

Volumn 38, Issue 11, 2004, Pages 1783-1788

  Brouse, Sara D ^a   Wiesehan, Vanessa G ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes; Bleeding; Glycoprotein IIb IIIa inhibitors; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEMOGLOBIN; HEPARIN; TIROFIBAN;

ADULT; AGE; AGED; BLEEDING; BODY WEIGHT; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG INFUSION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE COUNT;

AGED; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HEMORRHAGE; HOSPITALS, VETERANS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MALE; MIDDLE AGED; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TYROSINE;

EID: 7044247842     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E048     Document Type: Review

References (21)

1. American Heart Association. Heart disease and stroke statistics - 2004 update. Dallas: American Heart Association, 2003.
2. Ferguson JJ, Waly HM, Wilson MJ. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J 1998;135:S35-42.
3. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb/IIIa inhibitors. Am Heart J 1999;138:8263-75.
4. Package insert. ReoPro (abciximab). Indianapolis: Eli Lilly & Co., May 2001.
5. Package insert. Integrelin (eptifibatide). Kenilworth, NJ: Schering Corporation, June 2003.
6. Package insert. Aggrastat (tirofiban). West Point, PA: Merck & Co., May 2002.
7. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. Cochrane Database Syst Rev 2001;4:CD002130.
8. Blankenship JC. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. Am Heart J 1999;138:8287-96.
9. Rao AK, Pratt C, Berke A, Jaffe A, Ockene L, Schrieber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
10. Juran NB. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb/IIIa antiplatelet therapy. Am Heart J 1999;138:S297-305.
11. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139:S38-45.
12. Brown DL. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003;89:535-7.
13. Lopez LM. Clinical challenges of bleeding in percutaneous coronary intervention. Am J Health Syst Pharm 2003;60(suppl 3):S8-14.
14. The EPIC Investigators. Use of a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
15. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrelin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8.
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
17. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, et al. Modifiable risk factors for vascular access site complications of angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT-II trial. J Am Coll Cardiol 1998;31:1518-24.
18. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E, et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (the TACTICS-TIM1 18 trial). Am J Cardiol 2002;90:1246-9.
19. Moscucci M, Ricciardi M, Eagle KA, Kline E, Bates ER, Werns SW, et al. Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions. Am J Cardiol 1998;81:702-7.
20. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender. J Am Coll Cardiol 2000;36:381-6.
21. Jakovou I, Dangas G, Mehran R, Mintz GS, Lansky AJ, Aymong ED, et al. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients 75 years of age versus those <75 years of age. Am J Cardiol 2003;92:1083-6.